

Thomas Bachelot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2810030/publications.pdf>

Version: 2024-02-01

53
papers

9,200
citations

218677

26
h-index

144013

57
g-index

63
all docs

63
docs citations

63
times ranked

9368
citing authors

#	ARTICLE	IF	CITATIONS
1	Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 191-207.	2.5	0
2	Medical treatment for active breast cancer brain metastases. <i>Lancet Oncology</i> , The, 2022, , .	10.7	1
3	Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210770.	3.2	2
4	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	1.6	11
5	Treatment strategies for breast cancer brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 142-155.	6.4	117
6	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428.	7.0	16
7	Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 601-613.	2.5	16
8	Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-9.	4.0	9
9	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	2.8	9
10	Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. <i>European Journal of Cancer Care</i> , 2020, 29, e13169.	1.5	16
11	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
12	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	7.0	102
13	Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 555-560.	2.4	4
14	Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. <i>Breast</i> , 2020, 52, 50-57.	2.2	25
15	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
16	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203.	0.9	4
17	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 10757.	3.3	8
18	Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e12306.	3.7	27

#	ARTICLE	IF	CITATIONS
19	Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials. <i>Clinical Breast Cancer</i> , 2019, 19, 63-70.	2.4	8
20	Assessment of the efficacy of successive endocrine therapies in hormone receptorâ€“positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. <i>European Journal of Cancer</i> , 2019, 118, 131-141.	2.8	11
21	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000.	6.4	113
22	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	2.8	211
23	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 977.	7.1	48
24	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 87-100.	10.7	307
25	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial. <i>JMIR Research Protocols</i> , 2018, 7, e10487.	1.0	18
26	Optimal duration of adjuvant chemotherapy for high-risk node-negative (Nâ€“) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). <i>European Journal of Cancer</i> , 2017, 79, 166-175.	2.8	5
27	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 83570-83584.	1.8	18
28	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive nonâ€“metastatic breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 941-948.	2.4	24
29	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.1	242
30	PI3K targeting in breast cancer: the end of the beginning?. <i>Lancet Oncology</i> , The, 2016, 17, 696-697.	10.7	1
31	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 307-318.	2.5	101
32	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	27.0	1,390
33	Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptorâ€“Positive, HER2-Negative Early Breast Cancer. <i>Translational Oncology</i> , 2016, 9, 114-123.	3.7	27
34	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	1.6	203
35	TIF1Î³ interferes with TGFÎ²1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 453.	2.6	28
36	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2â€“ advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 94-104.	7.7	22

#	ARTICLE	IF	CITATIONS
37	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 13.	5.0	69
38	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1700-1710.	10.7	108
39	Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 125-133.	2.5	33
40	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIRO1/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	10.7	351
41	A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. <i>Molecular Oncology</i> , 2014, 8, 1441-1457.	4.6	32
42	Targeted treatments for breast cancer: a step forward. <i>Lancet Oncology</i> , The, 2013, 14, 438-439.	10.7	3
43	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013, 49, 2621-2632.	2.8	53
44	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 64-71.	10.7	622
45	Brain metastases from HER2-positive breast cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2013, 14, e3-e4.	10.7	2
46	Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of <i>de novo</i> or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. <i>International Journal of Cancer</i> , 2013, 133, 1589-1602.	5.1	42
47	mTOR inhibitors in advanced breast cancer: Ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013, 39, 742-752.	7.7	27
48	Reply to J.-H. Choi et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 511-511.	1.6	1
49	Health-related quality of life and disease symptoms in postmenopausal women with HR ⁺ , HER2 ⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	1.9	24
50	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor ⁺ Positive, Human Epidermal Growth Factor Receptor 2 ⁻ Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2718-2724.	1.6	630
51	Everolimus in Postmenopausal Hormone-Receptor ⁺ Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	27.0	2,474
52	Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series. <i>Clinical Breast Cancer</i> , 2009, 9, 118-121.	2.4	58
53	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. <i>Journal of Clinical Oncology</i> , 2004, 22, 3302-3308.	1.6	389